On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled rapid and equitable access to Vekluryﾮ (remdesivir), the first antiviral drug proven to be effective for the treatment of COVID-19 in the European Union (EU).

The agreement covered purchases of Veklury over the six months with an extendable option. In the EU, EEA and UK, Veklury is indicated for the treatment of COVID-19 in adult and adolescent patients with pneumonia requiring supplemental oxygen.